What is ADVAGRAF 1mg
ADVAGRAF 1mg is a prolonged-release oral capsule containing tacrolimus as the active ingredient. Tacrolimus belongs to the class of immunosuppressants used primarily to prevent organ rejection in patients who have undergone transplantation, including kidney, liver, or heart transplants.
The prolonged-release formulation allows for once-daily dosing, providing a more consistent and steady blood concentration of tacrolimus compared to immediate-release forms. This steady drug level helps reduce fluctuations that might otherwise increase the risk of rejection or toxicity, thereby improving patient compliance and outcomes.
- Active Ingredient: Tacrolimus
- Dosage Form: Hard gelatin capsules, prolonged-release
- Strength: 1 mg per capsule
- Packaging: 100 capsules per pack (two pouches of 50 capsules each, blister-packed)
- Indications: Prevention of rejection in kidney, liver, and heart transplant recipients
- Drug Class: Calcineurin inhibitor immunosuppressant
How to use ADVAGRAF 1mg
Using ADVAGRAF 1mg correctly is essential to maintain effective immunosuppression while minimizing risks:
- Dosage: Take the capsules once daily, ideally at the same time every day to maintain steady blood levels.
- Swallow whole: Do not crush, chew, or open the capsules, as this will disrupt the prolonged-release mechanism.
- Food: Capsules can be taken with or without food, but consistency in diet is recommended because food can influence tacrolimus absorption.
- Monitoring: Regular blood tests to monitor tacrolimus trough levels are critical to adjust dosing and avoid toxicity or under-immunosuppression.
- Missed dose: If you miss a dose, take it as soon as you remember unless it is close to the next scheduled dose. Do not double doses.
- Do not stop abruptly: Sudden discontinuation can lead to transplant rejection; any changes must be under medical supervision.
- Inform your healthcare provider: About all other medications, supplements, or herbal products you use to avoid interactions.
Mode of Action ADVAGRAF 1mg
Tacrolimus exerts its immunosuppressive effect by selectively inhibiting T-cell activation. The detailed mechanism is:
- Binding: Tacrolimus binds to an intracellular protein called FK-binding protein (FKBP-12).
- Inhibition: The tacrolimus-FKBP-12 complex inhibits calcineurin phosphatase, a key enzyme in the activation pathway of T-cells.
- Reduced cytokine production: By blocking calcineurin, tacrolimus prevents activation of nuclear factor of activated T-cells (NF-AT), which is essential for producing interleukin-2 (IL-2) and other cytokines.
- Immune suppression: This leads to reduced T-cell proliferation and function, thereby dampening the immune response that could attack the transplanted organ.
- Selective action: Tacrolimus primarily affects T-lymphocytes, which are central to cell-mediated immunity.
ADVAGRAF 1mg Interactions ADVAGRAF 1mg
ADVAGRAF interacts with many drugs that can affect its metabolism or enhance adverse effects. Key interactions include:
- CYP3A4 inhibitors (e.g., ketoconazole, erythromycin, clarithromycin, fluconazole): These can increase tacrolimus blood concentrations, raising the risk of nephrotoxicity and neurotoxicity.
- CYP3A4 inducers (e.g., rifampicin, carbamazepine, phenytoin, St. John’s Wort): These may reduce tacrolimus levels, increasing the risk of organ rejection.
- Nephrotoxic drugs (e.g., NSAIDs, amphotericin B, aminoglycosides): Combination may exacerbate kidney damage.
- Calcium channel blockers (e.g., diltiazem, verapamil): May increase tacrolimus levels.
- Grapefruit juice: Strong CYP3A4 inhibitor; can significantly increase blood levels of tacrolimus and should be avoided.
- Other immunosuppressants: Often given in combination but require careful monitoring to balance efficacy and toxicity.
Always inform your healthcare provider about all medications and supplements you take to manage these interactions properly.
Dosage of ADVAGRAF 1mg
Dosage must be individualized based on the type of transplant, patient weight, and blood tacrolimus levels. General dosage guidance:
- Initial dose: Typically 0.1–0.2 mg/kg/day administered once daily, beginning 12 to 24 hours post-transplantation.
- Maintenance dose: Adjusted according to blood trough levels, which typically target 5-15 ng/mL depending on time since transplant and transplant type.
- Therapeutic drug monitoring: Essential to tailor dosing and avoid toxicity or under-dosing.
- Special populations: Dose adjustments may be necessary in patients with hepatic or renal impairment, pediatric, or elderly patients.
- Missed doses: Should be taken as soon as possible but never double the dose.
Possible side effects of ADVAGRAF 1mg
Common and serious side effects of tacrolimus include:
- Nephrotoxicity: Most significant side effect, requiring frequent kidney function monitoring.
- Neurotoxicity: Manifested as tremors, headaches, seizures, insomnia, or rarely encephalopathy.
- Infections: Increased susceptibility due to immunosuppression, including bacterial, viral, and fungal infections.
- Hypertension: Elevated blood pressure is common during treatment.
- Gastrointestinal symptoms: Such as nausea, diarrhea, abdominal pain.
- Metabolic disturbances: Hyperglycemia, new-onset diabetes mellitus, hyperkalemia, hypomagnesemia.
- Other effects: Hair thinning or loss, rash, malaise, and electrolyte imbalances.
- Serious reactions: Signs of allergic reactions, severe infections, or neurological symptoms warrant immediate medical attention.
ADVAGRAF 1mg Contraindications ADVAGRAF 1mg
ADVAGRAF should not be used in:
- Known hypersensitivity: To tacrolimus or any component of the capsule.
- Active severe infections: As the immunosuppressive effect can worsen infections.
- Use with caution in severe hepatic impairment: Tacrolimus metabolism is hepatic, and impaired function may increase toxicity risk.
- Live vaccines: Contraindicated due to immunosuppression.
- Pregnancy and breastfeeding: Use only if clearly needed and under strict medical supervision due to potential fetal risks.
Storage of ADVAGRAF 1mg
Proper storage ensures the medication maintains efficacy and safety:
- Temperature: Store at controlled room temperature between 20°C and 25°C (68°F to 77°F).
- Protection: Keep capsules in original blister packs to protect from moisture and light exposure.
- Keep out of reach: Store away from children and pets.
- Do not freeze: Avoid extreme temperatures.
- Expiry: Do not use after the expiration date printed on the packaging.
ADVAGRAF 1mg features an exceptional active ingredient renowned for its potent effects, comprising Tacrolimus. This powerful formulation provides a superior solution for addressing diverse health concerns. With 1mg/Capsule concentration and an easily manageable Capsules (Hard Gelatin)/Prolonged Release, it remains a preferred option for countless individuals seeking effective treatment.
Introduction
All you need to know about ADVAGRAF 1mg .
Welcome to Dwaey, specifically on ADVAGRAF 1mg page.
This medicine contains an important and useful components, as it consists of Tacrolimus.
ADVAGRAF 1mg is available in the market in concentration 1mg/Capsule and in the form of Capsules (Hard Gelatin)/Prolonged Release.
HIKMA PHARMACEUTICALS is the producer of ADVAGRAF 1mg and it is imported from JORDAN,
The most popular alternatives of ADVAGRAF 1mg are listed downward .
-
Active Substance
-
Size
100Õs [50 s (10 s Blister x 5) Pouch x 2]
-
Indications
-
Type
Capsules (Hard Gelatin)/Prolonged Release
-
Company
Frequently Asked Questions
ADVAGRAF 1mg should be stored according to the instructions provided by HIKMA PHARMACEUTICALS.
In general, it is recommended to store ADVAGRAF 1mg in a cool, dry place, away from direct sunlight
and out of the reach of children.
The duration of treatment with ADVAGRAF 1mg may vary depending on the condition being treated
and the guidance of your healthcare provider. It is important to follow the prescribed treatment
plan and continue taking ADVAGRAF 1mg for the recommended duration, even if your symptoms improve.
If you have any concerns or questions about the duration of treatment, consult your healthcare provider.
It is important to check with your healthcare provider or read the medication label for specific
instructions regarding alcohol consumption while taking ADVAGRAF 1mg. Some medications, including
ADVAGRAF 1mg, may have interactions with alcohol that can reduce effectiveness, increase side
effects, or pose other risks to your health. It is best to follow the guidance provided by your
healthcare professional.
If you miss a dose of ADVAGRAF 1mg, take it as soon as you remember. However, if it is close
to the time for your next scheduled dose, skip the missed dose and continue with your regular dosing
schedule. Do not take a double dose to make up for a missed one unless advised by your healthcare provider.
No, do not stop taking ADVAGRAF 1mg without consulting your healthcare provider, even if your
symptoms improve. It is important to complete the full course of treatment as prescribed. Stopping
the medication prematurely may lead to a relapse or incomplete resolution of the condition. If you
have concerns about the duration of treatment, consult your healthcare provider for guidance.
It is important to consult your healthcare provider before taking ADVAGRAF 1mg if you are
pregnant or breastfeeding. They will be able to assess the potential risks and benefits based on your
specific situation. Please note that the safety and suitability of ADVAGRAF 1mg during pregnancy
or breastfeeding may depend on the active substance [Active Substance], concentration 1mg/Capsule,
and the specific recommendations of HIKMA PHARMACEUTICALS.
The effects of ADVAGRAF 1mg on your ability to drive or operate machinery can vary depending on
the active substance [Active Substance], concentration 1mg/Capsule, and individual factors.
Some medications may cause drowsiness, dizziness, or other side effects that can impair your judgment
or coordination. It is important to read the medication label or consult your healthcare provider to
understand any potential effects on your ability to perform tasks that require alertness.
The instructions for taking ADVAGRAF 1mg with or without food may vary depending on the medication
and the recommendations of HIKMA PHARMACEUTICALS. Some medications may be more effective when taken with
food to enhance absorption or reduce stomach irritation, while others may need to be taken on an empty
stomach for optimal absorption. Read the medication label or consult your healthcare provider for specific instructions.
The use of ADVAGRAF 1mg in children or elderly individuals may depend on various factors, including
the specific medication, type Capsules (Hard Gelatin)/Prolonged Release, and the recommendations of HIKMA PHARMACEUTICALS. Some
medications may have specific dosing instructions or precautions for these age groups. Consult your
healthcare provider or read the medication label for information regarding the safe and appropriate use
of ADVAGRAF 1mg in children or elderly individuals.
Dwaey
All medical information published on the Dwaey website aims to increase medical awareness and health education among users. However, it is not a substitute for professional medical advice. Always consult with a specialist doctor. We strongly advise against using any information or medicine found on the site without referring to your healthcare provider.
Related Products
0 Comments